DROOID DELIVERS THE
NEWS THAT'S
Trump Announces 100% Generic Drug Tariff, 200% Next Year
- U.S. President Donald Trump announced a 100% tariff on imported generic drugs starting August 1 2028 (as reported by CBS News), with the tariff slated to rise to 200% in August 2029 (as reported by CNBC).
- Patient-advocacy groups and Public Citizen warned the tariffs could raise prices, create shortages, and force rationing of essential medicines for millions.
- Generic drugs make up roughly 90% of U.S. prescriptions, underscoring the policy’s broad impact.
- Maker Sandoz said it will shut its Long Island plant by end-2026, citing tariff uncertainty.
- U.S. President Donald Trump announced a 100% tariff on imported generic drugs starting August 1, 2028 (as reported by CBS News), rising to 200% in 2029 (as reported by CNBC), targeting foreign suppliers.
- The tariffs, according to President Trump, are intended to protect the American people.
- A two-year transition period gives manufacturers time to consider U.S. production investments.
- Analysts warned the steep tariffs could raise prices or cause shortages if costs aren’t absorbed.
- U.S. President Donald Trump announced a 100% tariff on imported generic drugs starting August 1, 2028 (as reported by CBS News), rising to 200% in 2029 (as reported by CNBC).
- Health policy experts say the tariffs are unlikely to compel generic manufacturers to relocate production to the United States.
- The administration will invoke Section 232 of the Trade Expansion Act, though no order exists yet.
- Patented-medicine tariffs stay unchanged, and the Association for Accessible Medicines said more details are needed.
- Swiss generic drugmaker Sandoz announced it will shut its U.S. manufacturing plant on Long Island by the end of 2026, citing uncertainty over the proposed tariffs.
- Public Citizen warned the tariffs could trigger supply-chain shocks and force rationing of essential medicines.
- Within this story's sources, this angle appears mainly in Left-leaning coverage and receives less attention in Center- and Right-leaning coverage.
President George W. Bush invoked Section 232 in March 2002 to impose a 30 % steel tariff on $2.5 billion of U.S. imports; the WTO ruled it illegal on 11 Nov 2003 and the duties were lifted 4 Dec 2003. Trump revived Section 232 for steel/aluminum in 2018 and, on 2 Apr 2026, announced a 20 % tariff on generic drugs, echoing the earlier protectionist episode.
- U.S. President Donald Trump announced a 100% tariff on imported generic drugs starting August 1 2028 (as reported by CBS News), with the tariff slated to rise to 200% in August 2029 (as reported by CNBC).
- Patient-advocacy groups and Public Citizen warned the tariffs could raise prices, create shortages, and force rationing of essential medicines for millions.
- Generic drugs make up roughly 90% of U.S. prescriptions, underscoring the policy’s broad impact.
- Maker Sandoz said it will shut its Long Island plant by end-2026, citing tariff uncertainty.
- U.S. President Donald Trump announced a 100% tariff on imported generic drugs starting August 1, 2028 (as reported by CBS News), rising to 200% in 2029 (as reported by CNBC), targeting foreign suppliers.
- The tariffs, according to President Trump, are intended to protect the American people.
- A two-year transition period gives manufacturers time to consider U.S. production investments.
- Analysts warned the steep tariffs could raise prices or cause shortages if costs aren’t absorbed.
- U.S. President Donald Trump announced a 100% tariff on imported generic drugs starting August 1, 2028 (as reported by CBS News), rising to 200% in 2029 (as reported by CNBC).
- Health policy experts say the tariffs are unlikely to compel generic manufacturers to relocate production to the United States.
- The administration will invoke Section 232 of the Trade Expansion Act, though no order exists yet.
- Patented-medicine tariffs stay unchanged, and the Association for Accessible Medicines said more details are needed.
- Swiss generic drugmaker Sandoz announced it will shut its U.S. manufacturing plant on Long Island by the end of 2026, citing uncertainty over the proposed tariffs.
- Public Citizen warned the tariffs could trigger supply-chain shocks and force rationing of essential medicines.
- Within this story's sources, this angle appears mainly in Left-leaning coverage and receives less attention in Center- and Right-leaning coverage.
President George W. Bush invoked Section 232 in March 2002 to impose a 30 % steel tariff on $2.5 billion of U.S. imports; the WTO ruled it illegal on 11 Nov 2003 and the duties were lifted 4 Dec 2003. Trump revived Section 232 for steel/aluminum in 2018 and, on 2 Apr 2026, announced a 20 % tariff on generic drugs, echoing the earlier protectionist episode.
DON'T TAKE OUR WORD FOR IT,
SEE WHAT OUR USERS SAY
A Must-Have News for Staying Informed
This news app offers a beautifully designed,user-friendly experience that makes reading the news enjoyable and efficient . The app delivers high-quality journalism from trusted publishers,covering a wide range of topics including politics,entertainment,sports and local news. I love how the content is currated expertly,allowing me to personalize my feed based on my interests.
Nice App
Good to find unbiased news
Great App to Stay Informed Easily
I really like the app. I was looking for something that could give me summarized news about F1, and this does exactly what I needed. The other apps I tried were too opinionated and didn't offer much personalization. Drooid delivers news in short, card-style updates with images that make it visually appealing. The cool thing is that the app offers way more topics beyond F1- there's content for just about any interest. I'd recommend it to people like me - a bit lazy, but who want to stay informed without spending too much time reading.
Greatness
Drooid is great news app for my iPhone,I highly recommend it!
Loving it
Simple and straightforward layout. Refreshing new News App. Looking forward to using it as my go to for current events. Love the name!
Honestly, this app gave me both sides of the news stories. If you're like me, and are always looking for both sides of a story, this app is definitely a good one to check out
Great news app
With so many unreliable, misleading, and heavily editorialized stories passing for “news” these days, it can be a mental drain just pre-screening them for accuracy. Sorting the bad from the good is a best-use of AI, and occasional spot-checks have all come back good. I find myself going to it as my primary news source more and more!
Game changer for news consumption!
I’ve been using Drooid for a month now, and it has completely changed the way I consume news. The app delivers clear, concise, and balanced summaries that save me so much time while keeping me well-informed. I really appreciate how it presents multiple perspectives on each story and provides context without bias. The interface is clean and easy to use, and the transparency about sources builds trust. Great job — this is exactly what modern news apps should be like!
Amazing!
Curated and summarized news for easy reading,sources included. It's a great app for taking in your interests.
Needs Better Accessibility
I really like the concept of this app. I like the short summaries and the ability to see all sides. Like how it shows you both left-leaning and right-leaning opinions. I feel like that's something a lot more people need to see. However, as it stands at the moment, the usability with voiceover, the ios screenreader that allows blind people to use apple devices is bad. I'm able to read stories well enough but when it comes to interacting with them, especially commenting on them, it's not good at all. This short format would be great for blind and visually impaired people to get news, if these issues were improved upon.
Good Sources
Great digest of news from different sources
Very well designed news feed
DROOID BRINGS YOU THE FULL PICTURE.
We gather news from multiple trusted publishers, then our AI reads everything and delivers short, clear summaries, each reflecting a different perspective. Every summary links back to the original source, so you can explore further anytime.
